Event agenda
Thursday, 11 June 2026
13:00 - 13:30
13:30 - 13:35
Welcome by Immunity for Health
1 speaker
13:35 - 14:00
Antibody Horizons: Innovation, Translation and Clinical Impact – Hilde Revets, PHiRA Consulting/VUB
This talk gives an easy to understand look at how new antibody technologies are making treatments more precise and effective.
14:00 - 14:20
Bringing HER2 imaging to the clinic: from discovery to Phase 2b validation - Tony Lahoutte & Karine Clauwaert, UZ Brussels - Abscint
We share the development of ABSCINT’s HER2-targeted imaging platform, from concept to Phase 2b clinical validation in the HERMIA study. The results support its potential to reshape how HER2 expression is assessed and used in treatment decision-making.
2 speakers
14:20 - 14:32
Breaking Barriers: Delivering Biologicals to the Brain - Maarten Dewilde, KU Leuven
The limited number of biological therapies for central nervous system disorders is due to the blood–brain barrier, but recent breakthroughs are bringing a revolution within reach.
1 speaker
14:32 - 14:45
Intranasal convalescent plasma as prophylaxis against respiratory infections - Elise Wouters, Rode Kruis Vlaanderen
Intranasal convalescent plasma as prophylaxis against respiratory infections delivers antibody‑rich plasma directly to the upper respiratory mucosa to provide immediate, localized immune protection.
14:45 - 15:00
Q&A Session 1
A Q&A session with the session speakers, including questions from the audience, moderated by Prof. Niels Hellings - Hasselt University.
1 speaker
15:00 - 15:25
15:25 - 15:45
argenx's Immunology Innovation Program - Heleen Dewitte, argenx
Through innovation and fruitful partnership with academia, argenx has built a broad clinical development pipeline of differentiated antibody candidates that show promise in treating a variety of severe autoimmune and neurological disorders.
1 speaker
15:45 - 16:00
16:00 - 16:15
Beyond human health: mAb generation for companion animals - Markus Waldhuber, Zoetis
This presentation explores the unique challenges and opportunities in generating species-specific mAbs for veterinary use, bridging established human antibody engineering approaches with the emerging field of companion animal biologics.
1 speaker
16:15 - 16:30
Q&A Session 2
A Q&A session with the session speakers, including questions from the audience, moderated by Prof. Niels Hellings - Hasselt University.
1 speaker
16:30 - 17:30
16:30 - 17:30
Networking
- Reception Area
Meeting duration:15 minutes time slots